Resumen de Investigación
Dapagliflozin may improve RAAS markers in diabetes patients
Moderate confidence
Low bias
Última actualización 17 de junio de 2026Conclusión Clave:
This study investigated the effects of dapagliflozin on the renin-angiotensin-aldosterone system in patients with type 2 diabetes, finding significant changes in several metabolic parameters.
Estudio de un Vistazo
Participantes
Intervención
Dapagliflozin
Resultados
renin, BMI, HbA1c, Fasting Plasma Glucose, Triglycerides, Total Cholesterol, Systolic Blood Pressure, Diastolic Blood Pressure, Urinary Albumin-to-Creatinine Ratio, Insulin resistance, Serum creatinine
Financiamiento
No Patrocinado por la Industria
Guarda este estudio y agrega notas a tu biblioteca de investigación.
Efectos Principales
Renin levels increased significantly from baseline at 1-month visit (4.15 ng/L, p < 0.05)
BMI decreased by 0.87 kg/m²
HbA1c decreased by 1.62%
Resumen de Evidencia
| Intervention | Outcome | Measured Change | Study Effect |
|---|---|---|---|
 Dapagliflozin (Medications) |  BMI (Weight & Anthropometrics) | Decrease | Unclear |
Dapagliflozin (Medications) |  Diastolic blood pressure (Metabolic Health) | Decrease | Unclear |
Dapagliflozin (Medications) |  Fasting blood sugar (FBS) (Glycemic Control) | Decrease | Unclear |
Dapagliflozin (Medications) | HbA1c (Glycemic Control) | Decrease | Unclear |
Dapagliflozin (Medications) | Insulin resistance (Metabolic Health) | Decrease | Unclear |
Dapagliflozin (Medications) |  Renin (Clinical Outcomes) | Increase | Strong |
Dapagliflozin (Medications) |  Serum creatinine (Safety) | Increase | Unclear |
Dapagliflozin (Medications) | Systolic blood pressure (Metabolic Health) | Decrease | Unclear |
Dapagliflozin (Medications) | Total cholesterol (Metabolic Health) | Decrease | Unclear |
Dapagliflozin (Medications) | Triglycerides (Metabolic Health) | Decrease | Unclear |
Dapagliflozin (Medications) | Urinary albumin-to-creatinine ratio (Clinical Outcomes) | Decrease | Unclear |
Unlock Full Evidence Analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
La Evidencia Sugiere
- Renin increased by 4.15 ng/L, indicating hormonal changes
- BMI decreased by 0.87 kg/m², showing weight loss
- HbA1c decreased by 1.62%, reflecting better blood sugar control
A quién se aplica
- Adults diagnosed with type 2 diabetes
- Patients undergoing treatment with dapagliflozin
Tener en Cuenta
- Results may not apply to non-diabetic populations
- Further studies needed to assess long-term effects
- Potential implications for cardiovascular risk management
Entre Líneas
- Unclear effectiveness for some outcomes
- Limited generalizability due to specific population characteristics
- Short follow-up period may not capture long-term effects
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Already have an account?
Referencia de la Revista
Ningning W, Junfeng K, Ziming L, et al. The effects of dapagliflozin on the renin-angiotensin-aldosterone system in patients with type 2 diabetes and hypertension. PLOS One. 2025;20(11):e0336158. doi:10.1371/journal.pone.0336158
Connected Evidence
Discover how this study fits into the broader diabetes evidence landscape.
This study contributes to evidence on SGLT2 Inhibitors and Glycemic Control, SGLT2 Inhibitors and Renin.
Relaciones de evidencia relacionadas
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention–outcome relationships.
Incluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
Glycemic Control Evidence Hub
All studies measuring Glycemic Control
4 studies
outcome_hubMeasures Glycemic Control as a key outcome.
SGLT2 Inhibitors Evidence Hub
All studies on SGLT2 Inhibitors
4 studies
intervention_hubContributes to SGLT2 Inhibitors evidence base.
Blood Pressure Evidence Hub
All studies measuring Blood Pressure
2 studies
outcome_hubMeasures Blood Pressure as a key outcome.
Renin Evidence Hub
All studies measuring Renin
1 studies
outcome_hubMeasures Renin as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explora más en el archivo de evidencia
Jump to pre-filtered views in the evidence archive.
All studies on Dapagliflozin and HbA1c
Intervention: DapagliflozinOutcome: HbA1c
4 results
All studies on Dapagliflozin and Renin
Intervention: DapagliflozinOutcome: Renin
1 results
All studies on Dapagliflozin
Intervention: Dapagliflozin
4 results
All studies measuring HbA1c
Outcome: HbA1c
4 results
All studies measuring Renin
Outcome: Renin
1 results
Preguntas que esta evidencia ayuda a responder
Key clinical and research questions this study contributes to.
Does dapagliflozin improve HbA1c?
Based on connected evidence for Dapagliflozin and HbA1c.
Does dapagliflozin affect Renin in people with diabetes?
Exploring evidence on Dapagliflozin and Renin outcomes.
What does the evidence say about dapagliflozin and Systolic blood pressure?
Review of studies examining Dapagliflozin and Systolic blood pressure.
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.